Text Size

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

This study has been completed.
Sponsor:
Information provided by:
University of Vermont
ClinicalTrials.gov Identifier:
NCT00710255
First received: July 2, 2008
Last updated: January 12, 2010
Last verified: July 2008
History of Changes
  Purpose

This research is being conducted to help us better understand what causes exercise induced asthma. The investigators hypothesize that two types of chemicals, cysteinyl leukotrienes and adenosine, play an important role. The investigators will be measuring these chemicals in the exhaled breath of volunteers with exercise induced asthma as they undergo a test to mimic exercise induced asthma. The investigators will determine how the levels of these chemicals change in association with how lung function changes before, during and after an episode of exercise induced asthma.


Condition Intervention
Asthma, Exercise Induced
 Procedure: Hyperpnea challenge

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm Determined by Dynamic Analysis of Exhaled Breath Condensate.

Resource links provided by NLM:

Drug Information available for: Adenosine
U.S. FDA Resources

Further study details as provided by University of Vermont:

Primary Outcome Measures:
  • Change in level of cystLTs and adenosine [ Time Frame: Before and after hyperpnea challenge ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in pH of EBC and change in pulmonary function [ Time Frame: Before and after hyperpnea challenge ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: October 2007
Study Completion Date: July 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Asthmatics
Asthmatics with exercise induced bronchospasm
 Procedure: Hyperpnea challenge
5 minutes of dry air hyperpnea to induce bronchospasm

  Eligibility

Ages Eligible for Study:   12 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Asthmatics with exercise induced bronchospasm

Criteria

Inclusion Criteria:

  • Physician diagnosed asthma
  • Age 12-75 yrs
  • FEV1 > 70% predicted
  • HIB response > 10 %
  • No smoking last 6 mo and < 10 pack yrs
  • No URI last 4 weeks
  • No asthma exacerbation last 4 weks
  • Able to withhold SABA > 8 hrs and LABA > 24 hrs

Exclusion Criteria:

  • Other lung disease
  • Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00710255

Locations
United States, Vermont
Vermont Lung Center
Colchester, Vermont, United States, 05446
Sponsors and Collaborators
University of Vermont
Investigators
Principal Investigator: David A. Kaminsky, MD University of Vermont
  More Information

No publications provided

Responsible Party: David Kaminsky, MD, University of Vermont
ClinicalTrials.gov Identifier: NCT00710255     History of Changes
Other Study ID Numbers: CHRMS 08-023, Merck IISP 32710
Study First Received: July 2, 2008
Last Updated: January 12, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Vermont:
Asthma
Exercise induced bronchospasm
Hyperpnea induced bronchospasm
 leukotrienes
adenosine
exhaled breath condensate

Additional relevant MeSH terms:
Asthma
Asthma, Exercise-Induced
Bronchial Spasm
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
 Adenosine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anti-Arrhythmia Agents
Cardiovascular Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on May 22, 2013